Recital 8, Regulation (EU) 2022/256

In forcesince 22 Feb 2022

ECDC considers that appropriately validated rapid antigen tests that meet high specificity criteria of more than 98 % could be used to certify that a person has recovered from a past SARS-CoV-2 infection [https://www.ecdc.europa.eu/sites/default/files/documents/Options-for-the-use-of-rapid-antigen-tests-for-COVID-19-first-update.pdf]. The higher the specificity, the higher the test validity to be used for certifying a recovered individual.